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tes mellitus or in those with a high vascular risk profile. Treat-
ment of dyslipidemia with statins, anticoagulation therapy 
in atrial fibrillation, and carotid endarterectomy in symptom-
atic high-grade carotid stenosis are also effective for stroke 
prevention. Lifestyle factors that have been proven to re-
duce stroke risk include reducing salt, eliminating smoking, 
performing regular physical activity, and maintaining a nor-
mal body weight.  © 2015 S. Karger AG, Basel 
 Introduction 
 Stroke is one of the most common causes of death and 
is the main cause of persistent and acquired disability in 
adults worldwide. Considering demographic changes, a 
further increase in stroke rates is expected. Moreover, 
stroke is expected to increasingly affect younger patients. 
The World Health Organization refers to stroke as the 
incoming epidemic of the 21st century. Therefore, cur-
rently, strategies for stroke prevention are of prime im-
portance, particularly with regard to the recent studies 
suggesting that 85% of all strokes may be preventable  [1] . 
Lifestyle modification is of particular interest for stroke 
prevention, as the incidence of stroke has decreased by up 
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 Abstract 
 Background: According to the World Health Organization, 
stroke is the ‘incoming epidemic of the 21st century’. In light 
of recent data suggesting that 85% of all strokes may be pre-
ventable, strategies for prevention are moving to the fore-
front in stroke management.  Summary: This review discuss-
es the risk factors and provides evidence on the effective 
medical interventions and lifestyle modifications for optimal 
stroke prevention.  Key Messages: Stroke risk can be sub-
stantially reduced using the medical measures that have 
been proven in many randomized trials, in combination with 
effective lifestyle modifications. The global modification of 
health and lifestyle is more beneficial than the treatment of 
individual risk factors.  Clinical Implications: Hypertension is 
the most important modifiable risk factor for stroke. Effica-
cious reduction of blood pressure is essential for stroke pre-
vention, even more so than the choice of antihypertensive 
drugs. Indications for the use of antihypertensive drugs de-
pend on blood pressure values and vascular risk profile; thus, 
treatment should be initiated earlier in patients with diabe-
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to 42% in developed countries within the last 30 years, 
whereas an increase by more than 100% has been report-
ed in developing countries  [2] . This observation indicates 
the important role of lifestyle and diet; the prevalence of 
risk factors such as smoking, hyperlipidemia, or high 
blood pressure has decreased considerably, thereby in-
creasing awareness among the populations of high-in-
come countries. However, in low-income countries, in-
dustrialization has led to unfavorable food and lifestyle 
changes  [2] . This review aims to discuss effective lifestyle 
modifications and medical interventions for optimal 
stroke prevention. An overview of the evidence for the 
recommendations is shown in  table 1 .
 Medical Measures 
 Arterial Hypertension 
 Hypertension is the most important and modifiable 
risk factor for stroke. Uncontrolled hypertension is also a 
main cause of cognitive deficits and dementia. A reduc-
tion of systolic blood pressure (SBP) by 2 mm Hg was as-
sociated with stroke reduction by 25%, while reduction in 
diastolic blood pressure (DBP) led to stroke reduction by 
50%  [3] . The relationship between blood pressure and 
stroke risk is linear and continuous as the reduction of 
borderline hypertension (SBP 130–140 mm Hg and DBP 
85–89 mm Hg) was also associated with risk reduction of 
stroke. Treatment of isolated SBP in elderly patients is 
also preventive: reduction of SBP >160 mm Hg to 145 mm 
Hg in patients aged >80 years was associated with stroke 
reduction by 30% within 2 years  [4] .
 Efficacious reduction of blood pressure is much more 
important and essential for stroke prevention than the 
choice of antihypertensive drugs. The selection of drug 
class should be made based on comorbidities. Some stud-
ies and meta-analyses suggest a beneficial trend in favor 
of calcium antagonists and angiotensin-converting en-
zyme blockers  [5] , whereas beta blockers in hypertensive 
patients without heart disease seem to be less protective 
for stroke prevention. Recent studies indicate that a high 
variability in blood pressure is associated with a higher 
stroke risk, which again supports treatment with calcium 
antagonists  [6] . Furthermore, patients with metabolic 
risk factors who are treated with thiazide diuretics or beta 
blockers seem to have a higher risk for the new onset of 
diabetes mellitus  [7] .
 Indications for the use of antihypertensive drugs de-
pend on blood pressure values and the vascular risk pro-
file; thus, treatment should be initiated earlier in patients 
with diabetes mellitus or in those with a high vascular risk 
profile. In patients with a low risk profile and borderline 
blood pressure values, non-pharmaceutical treatment 
options should be used (e.g., low-salt diet, physical activ-
ity, or weight reduction). Antihypertensive drug treat-
ment is recommended for all patients with blood pressure 
>140/90 mm Hg, whereas the treatment goal in high-risk 
patients should be ideally blood pressure levels of <130/80 
mm Hg. 
 Dyslipidemia and Statins 
 The association between stroke and hypercholes-
terinemia is less clear, although it is an established risk 
factor for myocardial infarction. Many studies indicate 
an increased risk of ischemic stroke with higher serum 
cholesterol levels (>7 mmol/l), whereas lower cholester-
ol levels in patients with hypertension (SBP >145 mm 
Hg) tend to be associated with hemorrhagic stroke. Hy-
percholesterinemia is clearly related to carotid athero-
sclerosis  [8] , whereas HDL-cholesterol is inversely as-
sociated with the risk of ischemic stroke. Statins have 
been shown to prevent stroke markedly in patients with 
coronary heart disease, diabetes mellitus, or carotid ste-
nosis, whereas this was not the case for the use of fi-
brates. The action of statins is assumed to be mediated 
through pleiotropic effects (anti-inflammatory, immu-
nomodulatory, plaque stabilizer, vasodilatation)  [9] . 
While the use of statins is clearly indicated for second-
ary prevention after ischemic stroke due to artery ath-
eromatosis, it is controversial whether statins may 
 reduce stroke risk in the healthy population without 
vascular disease  [10] . The absolute risk reduction for 
Table 1.  Evidence for recommendations on the treatment and life-
style factors related to stroke
Randomized 
trials
Observational 
studies
Arterial hypertension ×
Diabetes mellitus ×
Dyslipidemia ×
Antithrombotics ×
Atrial fibrillation ×
Carotid stenosis ×
Vitamin supplementation ×
Dietary recommendations ×
Smoking ×
Physical activity ×
Alcohol ×
Overweight ×
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.2
44
.1
73
 - 
2/
20
/2
01
5 
4:
36
:2
8 
PM
 Sarikaya/Ferro/Arnold  Eur Neurol 2015;73:150–157
DOI: 10.1159/000367652
152
healthy people seems to be rather low (0.2% per year), 
and so the use of statins in general cannot be recom-
mended. 
 Diabetes Mellitus 
 Patients with diabetes mellitus have a higher risk of 
vascular events. According to a prospective observational 
study, patients with type 2 diabetes suffered more fre-
quently from stroke than from myocardial infarction 
 [11] . Diabetes promotes cerebral microangiopathy and 
causes lacunar type strokes. Current data indicate that 
metformin may be beneficial for stroke prevention in di-
abetes  [12] . Intense control of hyperglycemia rather re-
duces microvascular complications, whereas the effect on 
macrovascular complications such as stroke is not clear 
 [13] . Moreover, intense control of present vascular risk 
factors such as hypertension or dyslipidemia has been 
shown to efficiently reduce the risk of cardiovascular 
events in diabetic patients  [14] . In addition, the use of 
statins has been shown to significantly reduce stroke risk 
(by 21% for each 1 mmol/l decrease in LDL-cholesterol). 
 Carotid Stenosis 
 The prevalence of asymptomatic carotid stenosis 
>50% increases with age and in patients with coronary 
heart disease, smoking, and diabetes mellitus. On the 
other hand, patients with carotid stenosis have a 4-fold 
higher risk of myocardial infarction than stroke  [15] . 
While endarterectomy of symptomatic carotid stenosis 
is a proven and beneficial treatment for secondary 
stroke prevention, its value for asymptomatic stenosis 
remains controversial. Randomized trials from the 
nineties have suggested a benefit for surgery in asymp-
tomatic carotid stenosis of  ≥ 60% to  ≥ 70% (relative risk 
reduction by 50%), provided the perioperative compli-
cation risk is less than 3% and patients have a life expec-
tancy  ≥ 5 years  [16, 17] . Considering the absolute risk 
reduction of 1% per year, however, the treatment effect 
was rather low. Moreover, recent studies suggested a 
stroke risk of <1% per year for patients with asymptom-
atic carotid stenosis and treated with intensive medical 
therapy, which was primarily attributed to regular use 
of antihypertensive drugs and statins and lifestyle mod-
ification. This new observation questions the value of 
surgery in asymptomatic patients  [18] . Therefore, cur-
rent randomized studies such as SPACE-2 are investi-
gating the absolute benefit of asymptomatic carotid ste-
nosis. Percutaneous intervention by stenting is consid-
ered a justifiable alternative to surgery in symptomatic 
carotid stenosis, especially in patients younger than 70 
years. Considering asymptomatic stenosis, the current 
body of evidence is insufficient for recommending 
stents as standard therapy. 
 Intracranial Stenosis 
 Current  data recommend an aggressive medical treat-
ment of intracranial stenosis as angioplasty and stenting 
in symptomatic patients was clearly associated with a 
higher risk of adverse outcomes  [19] . Anticoagulation 
caused higher rates of intracranial hemorrhages than an-
tiplatelet agents and was not superior in preventing a 
 secondary ischemic stroke  [20] .
 Atrial Fibrillation 
 The prevalence of atrial fibrillation increases with 
age (1% in 60-year-old patients, 18% in patients aged 
>85 years). It is the leading cause of stroke in the elder-
ly and is associated with large infarcts and high mortal-
ity rates. A regular pulse palpation in patients aged >65 
years and electrocardiography in the case of arrhythmic 
heart rate is recommended by cardiology societies to 
detect atrial fibrillation and prevent ischemic stroke 
 [21] . The decision for anticoagulation in non-valvular 
atrial fibrillation is made according to the CHA 2 DS 2 -
VASc score  [21] . As compared to the former CHADS 2 -
score, the new score places more emphasis on age, gen-
der, and vascular co-morbidities of patients and recom-
mends anticoagulation at a score  ≥ 1 points, except for 
women without any other risk factors. Furthermore, the 
specificity in defining low-risk patients has also in-
creased; thus, no more aspirin is recommended for this 
group (score = 0 points). In general, aspirin is less effec-
tive for stroke prevention in atrial fibrillation. Antico-
agulation reduces the stroke risk by 70% in atrial fibril-
lation and the benefit of treatment in older patients with 
atrial fibrillation by far outweighs the bleeding risk, 
which can be estimated by HAS-BLED Score  [22, 23] . 
However, studies indicate an underuse of anticoagu-
lants due to physicians’ perception on the risk of major 
bleeding as excessively high, because of the presence of 
clinical risk factors such as falls. It has been calculated 
that the risk of subdural hematoma that happens as a 
result of falling is so small that persons with an average 
stroke risk of 5% per year must fall approximately 300 
times in a year for the risks of anticoagulation to out-
weigh its benefits  [24] . As compared to vitamin K-an-
tagonists, the new anticoagulants (thrombin inhibitor, 
factor Xa-antagonist) have the main advantages of eas-
ier usage and a higher safety profile, particularly a low-
er risk of intracranial hemorrhage. On the other hand, 
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the new oral anticoagulants may have the following dis-
advantages as compared with vitamin K-antagonists: 
short duration of action leading to increased stroke risk 
in case of poor compliance, lack of monitoring and an-
tidote in case of emergent surgery or bleeding, and 
higher costs.
 Patent Foramen Ovale 
 The best treatment for patent foramen ovale (PFO) in 
cryptogenic stroke is still under debate. Closure of PFO 
with Amplatzer devices seems reasonable in younger pa-
tients without vascular risk factors, whereas PFO in older 
stroke patients with vascular comorbidities is probably 
incidental and thus do not necessarily need a closure  [25, 
26] . The best medical treatment for PFO (antiplatelet vs. 
anticoagulant) is the subject of ongoing studies.
 Sleep Disordered Breathing 
 Sleep disordered breathing (SDB) has been increasing-
ly recognized as an independent risk factor for stroke  [27, 
28] . SDB can be the cause and the consequence of stroke 
 [29, 30] . The high frequency (50–70%) of SDB in stroke 
patients, often in the form of obstructive sleep apnea 
(OSA), justifies the routine implementation of screening 
tools such as respiratory polygraph or apnea check. In se-
vere OSA, treatment with continuous positive airway 
pressure (CPAP) may reduce the cardiovascular morbid-
ity and mortality, whereas the evidence for efficient stroke 
prevention is still limited  [31, 32] . 
 Antithrombotics 
 For primary stroke prevention, acetylsalicylic acid (as-
pirin) has been the most investigated antithrombotic 
drug. The Women’s Health Study reported a stroke re-
duction by 17% in healthy women taking 100 mg aspirin 
every 2 days as compared to placebo; however, the differ-
ence was statistically non significant  [33] . In the Physi-
cians’ Health Study, no stroke prevention was observed 
in men treated with aspirin  [34] . A recent meta-analysis 
including 95,000 participants found no association be-
tween aspirin and primary stroke prevention, in either 
women or men, whereas the rates of gastrointestinal 
bleeding were significantly increased in the aspirin arm 
 [35] . Current data do not support a general use of aspirin 
for stroke prevention in the healthy population or in pa-
tients with diabetes mellitus  [36] . On the other hand, an-
tithrombotics including aspirin, clopidrogel, and dipyri-
damol are clearly indicated for secondary stroke preven-
tion in patients with ischemic stroke (relative risk 
reduction by 20–25%). 
 Lifestyle Modification 
 Salt 
The average salt intake in most Western countries is 
close to 10 g a day (and much higher in many Eastern 
 European and Asian countries), whereas international 
recommendations suggest that average population salt 
intake should be less than 5–6 g per day  [37] . Intake of 
higher salt amounts is associated with higher risk for isch-
emic and hemorrhagic stroke  [37] . About 20% of all in-
tracerebral hemorrhages are assumed to result from add-
ing salt to food  [38] . Moreover, reduction of dietary salt 
intake by half a teaspoon was associated with a reduction 
of cardiovascular events by 20%  [39] . The risk is assumed 
to result from increased blood pressure, leading to fibro-
sis in the arteries, kidneys, and heart  [40] . Reduction of 
dietary salt intake by a teaspoon (equal to 5–6 g salt) has 
been shown to reduce systolic and diastolic blood pres-
sure by 7 and 4 mm Hg, respectively, in hypertensive pa-
tients, whereas blood pressure reduction in patients with 
resistant hypertension was much higher (systolic by 23 
mm Hg and diastolic by 9 mm Hg, respectively)  [41, 42] . 
Of note, many people consume prepared foods, which 
contain a lot of salt and this makes control of salt intake 
difficult.
 Smoking 
 Cigarette smoking is an independent risk factor for 
stroke and potentiates the effect of other risk factors such 
as hypertension or hormone replacement therapy. The 
mechanism is due to reduced endogenous fibrinolysis 
and increased thrombocyte activity. Recent studies also 
suggest an association between passive smoking and 
stroke. Stroke risk was reduced by 50% one year after 
quitting smoking, and was comparable to that of non-
smokers 5 years later. 
 Physical Activity 
 Regular physical activity decreases stroke risk by 25–
30% through favorable effects on other vascular risk fac-
tors such as hypertension, hyperlipidemia, and over-
weight. The dose-effect relation is controversial, howev-
er; thus, it is not clear whether maximal physical activity 
leads also to maximal stroke reduction.
 Overweight 
 Each unit increase in body mass index (BMI) has been 
suggested to increase stroke risk by 5%. However, stroke 
mortality is also increased in underweight patients. Mark-
ers of abdominal obesity such as waist-to-hip ratio or 
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waist circumference are reported to correlate better with 
stroke risk. While obesity is an established risk factor for 
stroke occurrence, recent studies report decreased mor-
tality risk in obese stroke patients as compared to normal 
weight patients (‘obesity paradox’). To date, however, 
randomized trials on risk modification by weight reduc-
tion are lacking.
 Alcohol 
 The association between alcohol consumption and 
stroke risk is J-shaped: while slight to moderate alcohol 
intake ( ≤ 2 drinks per day for men and  ≤ 1 drink per day 
for women, respectively) may reduce stroke risk by 30%, 
higher consumption significantly increases the risk of 
stroke.
 Vitamins 
 There is robust evidence from many randomized trials 
that supplementation with vitamins A, C, E, or beta-car-
otene does not reduce the risk of stroke. Moreover, in-
creased mortality rates have been observed for regular 
substitution with beta-carotene and vitamins A and E. 
Although hyperhomocysteinemia is a known risk factor 
for stroke and serum levels of homocysteine can be low-
ered by treatment with folic acid and vitamin B12, ran-
domized trials did not prove stroke prevention by regular 
folate supplementation  [43] . Vitamin B3 (niacin) was re-
ported to reduce stroke risk in former studies, while 
statins were not used regularly. Supplementation with ni-
acin increased HDL-cholesterol levels in patients treated 
with statins, but did not reduce stroke rates  [44] . 
 Potassium 
 Several observational studies and a meta-analysis have 
indicated that a higher potassium intake is associated 
with a reduction of stroke risk by 21% (relative risk 0.79, 
95% CI 0.60–0.90)  [45] . The effect seems to be dose-de-
pendent: every increase in potassium intake by 1 g per day 
resulted in a reduction of stroke risk by 11%  [46] . The 
mechanism is probably partially mediated by the reduc-
tion of blood pressure  [47] . 
 Calcium 
 Randomized trials have shown that calcium supple-
mentation of >500 mg per day was associated with a sig-
nificant risk for myocardial infarction and a trend toward 
an increase in stroke  [48] . A meta-analysis of 3 placebo-
controlled trials including >20,000 patients showed simi-
lar results for the combined supplementation of calcium 
and vitamin D  [49] .
 Fats 
 Current studies indicate no significant association 
between stroke risk and the amount of fat intake, fat 
origin (animal vs. vegetable), and types of fats (saturated 
vs. polyunsaturated)  [50, 51] . Consumption of industri-
ally produced trans fats or saturated fatty acids, how-
ever, have been shown to increase the risk of coronary 
heart disease  [52, 53] . Although marine-derived, ome-
ga-3 polyunsaturated fatty acids (from oily fish such as 
salmon or herring) have been reported to significantly 
reduce the risk of cardiovascular deaths in several ran-
domized trials, no significant effect on stroke preven-
tion has been demonstrated to date  [54, 55] . On the oth-
er hand, the consumption of plant-derived omega-3 
polyunsaturated fatty acids (from vegetable oils such as 
walnut, flaxseed, or soybean) has been reported to de-
crease stroke risk according to an observational study, 
although this needs to be confirmed in randomized 
 trials  [56] .
 Protein and Carbohydrates 
 The amount of protein intake and protein type (animal 
vs. vegetable) does not seem to be a risk factor for stroke 
 [57] . Consumption of foods and liquids with added sug-
ars and high dietary glycemic indices increases the risk 
for overweight, diabetes mellitus, and coronary heart dis-
ease  [58] . Increased stroke mortality was reported among 
the Japanese people with high carbohydrate intake  [59] .
 Foods and Beverages 
 Regular fish consumption was associated with a re-
duced stroke risk as reported by several observational 
studies  [60] , whereas daily meat consumption is shown 
to increase the risk of stroke  [61] . Increased intake of 
fruits and vegetables (>5 servings per day) significantly 
reduce the stroke risk, whereas vegetable intake alone did 
not prevent strokes  [1, 62] . The mechanism is not clearly 
known, although reduction of blood pressure is thought 
to play an important role. A recent study reported that 
high plasma levels of lyocopene (e.g., found in tomatoes) 
were associated with a reduced risk of stroke by 50% 
 [63] . Moderate consumption (3–4 cups) of coffee or tea 
has been shown to reduce stroke risk as compared with 
no consumption  [64, 65] . The mechanism may be due to 
their antioxidative effects and improved endothelial 
 function. Chocolate consumption was also associated 
with lower rate of stroke and cardiovascular disease, pos-
sibly mediated by the antiinflammatory and antithrom-
botic effects of cocoa  [66] . Finally, the Mediterranean 
diet has recently been reported to reduce stroke risk  [67] .
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 Global Lifestyle Modification 
 Global modification of lifestyle has been shown to be 
more beneficial than the treatment of single risk factors. 
Patients fulfilling all 5 criteria of low-risk lifestyle (no 
smoking, regular physical activity  ≥ 30 min per day, 
healthy nutrition, moderate alcohol consumption, BMI 
<25 kg/m 2 ) had a reduced stroke risk by 80% as compared 
to patients fulfilling none of these criteria  [68] .
 Conclusions 
 In summary, stroke risk can be substantially reduced 
using the medical measures proven in many randomized 
trials. Arterial hypertension is by far the most important 
risk factor for stroke, whereas treatment of dyslipidemia 
with statins will further reduce the stroke risk. Antico-
agulation in atrial fibrillation and carotid endarterectomy 
in symptomatic high-grade carotid stenosis are also very 
efficient in stroke prevention, whereas the general use of 
aspirin, statins, or vitamins cannot be recommended for 
healthy people. Observational data strongly indicate that 
lifestyle modifications such as healthy diet, cessation of 
smoking and alcohol overuse, regular physical activity 
and achievement of normal body weight are beneficial for 
stroke prevention. However, one should consider that 
most lifestyle recommendations rely on case-control and 
epidemiological studies, which may be hampered by bias. 
The main challenge will be to educate and convince the 
population on the benefits that can be expected from 
healthy lifestyle and nutrition, as smoking and some di-
etary habits may rather be considered addictions. There-
fore, structured therapy programs may be warranted in 
many situations.
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